Noticias de HIMS_US
Noticias del mercado
Últimas noticias sobre HIMS_US — 694 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
NEW YORK, Aug 31 (Reuters) - Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as it continues to expand its international business. Hims finalized its acquisition of Australian digital health platform Eucalyptus, including its Sydney-based men
The Federal Trade Commission, along with California and Utah consumer protection agencies, sued Hims & Hers Health, Inc. for allegedly charging customers immediately after intake forms without clear disclosure and making subscription cancellations difficult. The FTC also claims the company misled consumers about privacy by sharing health data with third parties like Meta and Snap. Following the lawsuit announcement, Hims & Hers stock fell 14.73% to $25.00 per share. Investors and those affected are encouraged to contact Kaplan Fox & Kilsheimer LLP, which is investigating potential securities violations related to these allegations.
Enclomiphene Market worth USD 0.8 billion in 2026 is growing at a CAGR of 9.6% to reach USD 2.0 billion by 2036. Hims & Hers Health, Inc., Enhanced Group Inc., Mangoceuticals, Inc., BioScience Health Innovations, Inc., Maximus, SynergenX and West Bengal Chemical Industries Limited.
Hims faces an estimated $75,000 surcharge and must lower its dispute rate below 1.5%.
On August 18, 2026, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum told CNBC that a Federal Trade Commission lawsuit over the company’s data-sharing and subscription practices “misunderstands how the company works.” He defended the company’s compounded GLP-1 drug sales as having helped lower prices for weight-loss treatments. Why This Matters Hims & Hers […]
On August 21, 2026, Bloomberg reported that Hims & Hers Health, Inc. (NYSE:HIMS) was enrolled in Visa Inc. (NYSE:V)’s Acquirer Monitoring Program after customer credit card disputes in its weight-loss subscription business exceeded acceptable levels in July. Each dispute carries an $8 surcharge, resulting in a bill of nearly $75,000 due in September, and Hims […]
NEW YORK, NY - August 27, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).
Página 5 de 35